FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burd	len							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					0.			., 00											
1. Name and Address of Reporting Person* Gasser Elizabeth Anne						2. Issuer Name and Ticker or Trading Symbol TANDEM DIABETES CARE INC TNDM								5. Relationship of Reportir (Check all applicable) Director			10% Ow		
(Last) (First) (Middle) 12400 HIGH BLUFF DRIVE					05/	3. Date of Earliest Transaction (Month/Day/Year) 05/15/2024									below) below) EVP, Chief Strategy Officer				
(Street)	reet) AN DIEGO CA 92130				4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	·	(Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Inst								ant to a co	ion 10.		ı plan tha	it is intende	d to	
1 Title of	Socurity (Inc		le I - No	n-Deriv		_	Curiti 2A. Dee		quired,	Dis	1			Ily Owned		6. Own	nershin .	7. Nature	
1. Title of Security (Instr. 3)				Date (Month/Day/Year)		ar) i	Execution Date,		Transaction Code (Instr.					d Securiti Benefic Owned	Securities Beneficially Owned Following Reported		Direct Indirect tr. 4)	of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) ((D)	Price	Transac	saction(s) r. 3 and 4)			(
Common Stock				05/15/2024		-			A		813(1) A	\$15.	64 7,	7,236		D		
Common Stock				05/15	05/15/2024				M		162	A	\$0	7,	7,398		D		
Common Stock				05/15	05/15/2024				F ⁽²⁾		58	D	\$47.	37 7,	7,340		D		
Common Stock					/15/2024				M		474	A	\$0	7,	7,814		D		
Common Stock 0					5/2024				F ⁽²⁾		170	D	\$47.	7,644		D			
Common	Stock			05/15	/2024		M		6,012	2 A	\$0	13	3,656		D				
Common Stock 05/15/					5/2024	/2024		F ⁽²⁾		2,146	6 D	\$47.	7 11,510]	D			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of	3. Transaction Date (Month/Day/Year)		(e.g., p		call	5. N of Deri			ercis	able and		urities) nd of s	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial	C	0. Ownership Form: Direct (D)	11. Nature of Indirect Beneficial Ownershi	
(mon o)	Derivative Security		(montas 2 ay				Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)						e Security	(Owned Following Reported Transactio (Instr. 4)	(1	or Indirect I) (Instr. 4)	(Instr. 4)	
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares						
Restricted Stock Unit ⁽³⁾	(4)	05/15/2024			M			162	(5)		(5)	Common Stock	162	\$0	650		D		
Restricted Stock Unit ⁽⁶⁾	(4)	05/15/2024			М			474	(7)		(7)	Common Stock	474	\$0	1,897		D		
Restricted Stock	(9)	05/15/2024			M			6,012	(10)		(10)	Common	6,012	\$0	12,025	5	D		

Explanation of Responses:

- 1. The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 16, 2023 through May 15, 2024. This transaction is also exempt under Rule 16b-3(c).
- 2. Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
- 3. Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).
- 4. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.
- 5. RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.
- 6. Awarded on May 25, 2022 pursuant to the 2013 Plan.
- 7. RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.
- 8. Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan).
- 9. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. 10. RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.